Linezolid for XDR-TB?

In a small phase IIa study, most patients experienced culture conversion when linezolid was added to their existing regimens, but drug-related adverse events were common.

Data from in vitro susceptibility tests and retrospective analyses suggest that linezolid may offer benefit to patients with extensively drug-resistant tuberculosis (XDR-TB). Now, investigators have conducted a prospective, phase IIa trial of this agent in adults with chronic XDR-TB who had not responded to any available antibiotic regimen during the preceding 6 months.

Patients were enrolled at two medical centers in South Korea and were randomized to receive 600 mg of linezolid daily (in addition to their existing regimens) starting immediately or 2 months later. The primary end point was sputum-culture conversion — defined as negative sputum samples on solid (Löwenstein-Jensen) medium for 3 consecutive weeks — with data censored at 4 mont…

Reviewing Author

Larry M. Baddour, MD

Disclosures

RoyaltiesUpToDate, Inc. (Authorship duties)

Larry M. Baddour, MD

Disclosures

RoyaltiesUpToDate, Inc. (Authorship duties)

Linezolid for XDR-TB?

Topics

Reviewing Author